CG Oncology, Inc. CGON
72.64 USD -2.10 (-2.81%)
At closeNov 11, 2026, 4:17 AM EST
73.00 +0.36 +0.50%
Pre-market · Nov 11, 4:17 AM ET
71.26 Day range 74.95
35.80 52-week range 80.97
- YTD
- +74.95%
- 1 year
- +80.61%
News
benzinga.com Guggenheim Maintains Buy on CG Oncology, Lowers Price Target to $89 Guggenheim analyst Michael Schmitz maintains CG Oncology (NASDAQ:CGON) with a Buy and lowers the price target from $90 to $89.
defenseworld.net CG Oncology, Inc. $CGON Stock: Candriam S.C.A. Cuts Position Candriam S.C.A. lessened its position in CG Oncology, Inc. (NASDAQ: CGON) by 20.0% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 375,362 shares of the…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Obsidian Therapeutics (NASDAQ:OBX) stock increased by 27.7% to $12.26 during Friday's regular session. The company's market cap stands at $593.0 million. TransMedics Group (NASDAQ:TMDX)…
zacks.com CG Oncology, Inc. (CGON) Reports Q3 Loss, Beats Revenue Estimates CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.57 per share a year ago.- benzinga.com CG Oncology Q3 EPS $(0.64) Beats $(0.82) Estimate, Sales $1.604M Beat $643.584K Estimate CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.82) by 21.95 percent. This is a 12.28 percent decrease over losses of $(0.57)…
globenewswire.com CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September 30, 2026, and provided business updates.